Aileron Therapeutics, Inc. (ALRN) Income Statement Analysis

See more : SolarWorld Aktiengesellschaft (SRWRF) Income Statement Analysis – Financial Results

Complete financial analysis of Aileron Therapeutics, Inc. (ALRN) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Aileron Therapeutics, Inc., a leading company in the Biotechnology industry within the Healthcare sector.

You may be interested

Aileron Therapeutics, Inc. (ALRN)

Industry: Biotechnology

Sector: Healthcare

Website: https://www.aileronrx.com

About Aileron Therapeutics, Inc.

Aileron Therapeutics, Inc. operates as a clinical stage chemoprotection oncology company in the United States. The company is developing ALRN-6924, which is in Phase 1 trial for solid tumor and lymphoma; Phase 2a clinical trial to treat peripheral T-cell lymphoma; Phase I clinical trial for the treatment of acute myeloid leukemia (AML) and advanced myelodysplastic syndrome (MDS); Phase 1b trial to test the combination of ALRN-6924 and cytarabine, or Ara-C, in patients with MDS; and a Phase 2a combination trial of ALRN-6924 and palbociclib in patients with tumors harboring MDM2 amplifications co-amplifications, as well as for patients with p53-mutated small cell lung cancer that has completed Phase 1b clinical trial. It has a license agreement with Dana-Farber Cancer Institute and Harvard College; and Umicore Precious Metals Chemistry USA, LLC. The company was formerly known as Renegade Therapeutics, Inc. and changed its name to Aileron Therapeutics, Inc. in February 2007. Aileron Therapeutics, Inc. was incorporated in 2001 and is based in Boston, Massachusetts.

Metric	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013
Revenue	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	22.35M
Cost of Revenue	119.00K	169.00K	121.00K	163.00K	155.00K	218.00K	95.00K	232.00K	325.00K	9.33M	12.23M
Gross Profit	-119.00K	-169.00K	-121.00K	-163.00K	-155.00K	-218.00K	-95.00K	-232.00K	-325.00K	-9.33M	10.12M
Gross Profit Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	45.29%
Research & Development	3.99M	17.97M	17.01M	11.17M	17.66M	18.45M	14.24M	10.28M	7.83M	9.33M	12.23M
General & Administrative	11.36M	9.68M	9.60M	9.33M	12.29M	13.45M	8.77M	7.89M	5.06M	6.70M	6.84M
Selling & Marketing	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
SG&A	11.36M	9.68M	9.60M	9.33M	12.29M	13.45M	8.77M	7.89M	5.06M	6.70M	6.84M
Other Expenses	928.00K	318.00K	441.00K	-800.00K	0.00	0.00	0.00	-18.17M	0.00	0.00	0.00
Operating Expenses	16.28M	27.65M	26.61M	20.50M	29.96M	31.90M	23.01M	18.17M	12.89M	6.70M	6.84M
Cost & Expenses	16.28M	27.65M	26.61M	20.50M	29.96M	31.90M	23.01M	18.17M	12.89M	16.03M	19.07M
Interest Income	0.00		0.00	0.00	587.00K	355.00K	404.00K	46.00K	13.00K	10.00K	6.00K
Interest Expense	0.00		0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Depreciation & Amortization	119.00K	169.00K	121.00K	163.00K	155.00K	218.00K	95.00K	232.00K	325.00K	585.00K	774.00K
EBITDA	-15.61M	-27.48M	-26.48M	-20.33M	-29.80M	-31.33M	-23.01M	-17.94M	-12.57M	-15.44M	4.06M
EBITDA Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	18.16%
Operating Income	-16.28M	-27.65M	-26.61M	-20.50M	-29.96M	-31.90M	-23.01M	-18.17M	-12.89M	-16.03M	3.28M
Operating Income Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	14.69%
Total Other Income/Expenses	544.00K	318.00K	441.00K	-661.00K	587.00K	355.00K	404.00K	46.00K	13.00K	10.00K	6.00K
Income Before Tax	-15.73M	-27.33M	-26.21M	-21.16M	-29.37M	-31.55M	-22.60M	-18.12M	-12.88M	-16.02M	3.29M
Income Before Tax Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	14.72%
Income Tax Expense	0.00	-318.00K	-441.00K	661.00K	-587.00K	355.00K	34.00K	0.00	0.00	43.00K	3.10M
Net Income	-15.73M	-27.01M	-25.76M	-21.82M	-28.78M	-31.55M	-22.60M	-18.12M	-12.88M	-16.07M	194.00K
Net Income Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.87%
EPS	-3.42	-5.95	-5.80	-12.52	-23.46	-42.81	-60.74	-33.21	-23.60	-845.63	10.21
EPS Diluted	-3.42	-5.95	-5.80	-12.52	-23.46	-42.81	-60.74	-33.21	-23.60	-844.96	10.85
Weighted Avg Shares Out	4.60M	4.54M	4.44M	1.74M	1.23M	736.91K	372.15K	545.72K	545.72K	19.00K	19.00K
Weighted Avg Shares Out (Dil)	4.60M	4.54M	4.44M	1.74M	1.23M	736.91K	372.15K	545.72K	545.72K	19.02K	17.89K

Bears are Losing Control Over Aileron Therapeutics, Inc. (ALRN), Here's Why It's a 'Buy' Now

April 4, 2023zacks.com

After losing some value lately, a hammer chart pattern has been formed for Aileron Therapeutics, Inc. (ALRN), indicating that the stock has found support. This, combined with an upward trend in earnings estimate revisions, could lead to a trend reversal...

Aileron Therapeutics, Inc. (ALRN) Could Find a Support Soon, Here's Why You Should Buy the Stock Now

March 14, 2023zacks.com

Aileron Therapeutics, Inc. (ALRN) appears to have found support after losing some value lately, as indicated by the formation of a hammer chart. In addition to this technical chart pattern, strong agreement among Wall Street analysts in revising earnings estimates...

What Makes Aileron Therapeutics, Inc. (ALRN) a New Buy Stock

December 29, 2022zacks.com

Aileron Therapeutics, Inc. (ALRN) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Aileron Therapeutics, Inc. (ALRN) Moves to Buy: Rationale Behind the Upgrade

November 4, 2022zacks.com

Aileron Therapeutics, Inc. (ALRN) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

Aileron Therapeutics to Present and Participate in a Fireside Chat at the Ladenburg Thalmann 2022 Healthcare Conference

September 22, 2022globenewswire.com

BOSTON, Sept. 22, 2022 (GLOBE NEWSWIRE) -- Aileron Therapeutics (Nasdaq: ALRN), a chemoprotection oncology company that aspires to make chemotherapy safer and thereby more effective to save more patients' lives, today announced that Manuel Aivado, M.D., Ph.D., President and Chief...

Penny Stocks to Buy on August 8th? 3 to Watch

August 8, 2022pennystocks.com

Here's what you need to know about buying penny stocks on August 8th The post Penny Stocks to Buy on August 8th? 3 to Watch appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

How to Trade Penny Stocks in August 2022

August 7, 2022pennystocks.com

What you need to know about trading penny stocks in August The post How to Trade Penny Stocks in August 2022 appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

3 Oversold Biotech Stocks to Buy Now

May 19, 2022investorplace.com

Looking for oversold biotech stocks? These three have all seen significant drops this year despite promising catalysts for the future.

Aileron Therapeutics to Present at the H.C. Wainwright Global Investment Conference

May 17, 2022globenewswire.com

BOSTON, May 17, 2022 (GLOBE NEWSWIRE) -- Aileron Therapeutics (Nasdaq: ALRN), a chemoprotection oncology company that aspires to make chemotherapy safer and thereby more effective to save more patients' lives, today announced that Manuel Aivado, M.D., Ph.D., President and Chief...